PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26124325-11	2015	We demonstrated a statistically significant lapatinib- and gefitinib-induced repression of cyclin D1, MMP9 and beta-catenin in CERV196 cells dependent on incubation time.	Gefitinib	59-68	cyclin D1	Homo sapiens	91-100	
28247504-7	2017	Co-treated cells had greater reductions in gefitinib-induced CYP1A1/CYB1B1, EGFR, cyclin D1, p-Akt (Ser473), and survivin mRNA/protein expression, as well as an increase in p-p53 (Ser15).	Gefitinib	43-52	cyclin D1	Homo sapiens	82-91	
15570011-0	2004	Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines.	Gefitinib	147-156	cyclin D1	Homo sapiens	12-21	
15570011-3	2004	Therefore, we examined the relationship between deregulated cyclin D1 expression and sensitivity to gefitinib to determine whether this frequently occurring oncogenic change affected the cellular response to gefitinib.	Gefitinib	100-109	cyclin D1	Homo sapiens	60-69	
15570011-7	2004	SCC 9 clones overexpressing cyclin D1 continued to proliferate and maintained their S-phase fraction when treated with gefitinib, whereas empty vector control clones and the parental SCC 9 cells were profoundly inhibited and displayed marked reductions in S-phase.	Gefitinib	119-128	cyclin D1	Homo sapiens	28-37	
15570011-8	2004	The resistance of cyclin D1-overexpressing clones and cyclin D1-amplified cell lines was associated with maintenance of cyclin D1 expression after gefitinib treatment.	Gefitinib	147-156	cyclin D1	Homo sapiens	18-27	
15570011-8	2004	The resistance of cyclin D1-overexpressing clones and cyclin D1-amplified cell lines was associated with maintenance of cyclin D1 expression after gefitinib treatment.	Gefitinib	147-156	cyclin D1	Homo sapiens	54-63	
15570011-8	2004	The resistance of cyclin D1-overexpressing clones and cyclin D1-amplified cell lines was associated with maintenance of cyclin D1 expression after gefitinib treatment.	Gefitinib	147-156	cyclin D1	Homo sapiens	54-63	
27959426-16	2017	Phosphorylation of CREB and induction of c-fos, cyclin D1 and aromatase expression by 17beta-estradiol were all prevented by gefitinib.	Gefitinib	125-134	cyclin D1	Homo sapiens	48-57	
26288223-7	2015	The results of an EGFR-silencing study using siRNA showed that gefitinib and erlotinib affected eIF2alpha phosphorylation and cyclin-D1 expression independent of EGFR inhibition.	Gefitinib	63-72	cyclin D1	Homo sapiens	126-135	
26124325-12	2015	CONCLUSION: Cyclin D1 and MMP9 expression profiles may represent an early measure of sensitivity and level of response to lapatinib and gefitinib.	Gefitinib	136-145	cyclin D1	Homo sapiens	12-21	
23255952-5	2013	Gefitinib treatment caused cell cycle arrest predominantly at the G1 phase, which is associated with TOB1 nuclear translocation and its interaction with cyclin D1.	Gefitinib	0-9	cyclin D1	Homo sapiens	153-162	
23255952-7	2013	These results suggest that TOB1 interaction with cyclin D1 and nuclear translocation is directly involved in the gefitinib-induced anti-proliferative cell cycle arrest.	Gefitinib	113-122	cyclin D1	Homo sapiens	49-58	
19946741-4	2010	Treatment with the gefitinib/trastuzumab combination produced, as compared with a single agent, a more prolonged blockade of AKT and MAPK activation, a more pronounced accumulation of cells in the G0/G1 phase of the cell cycle, a more significant increase in the levels of p27(kip1) and of hypophosphorylated pRb2, and a decrease in the levels of Cyclin D1 and survivin.	Gefitinib	19-28	cyclin D1	Homo sapiens	347-356	
18803287-7	2008	In parallel, gefitinib downregulated constitutively phosphorylated HER2 and HER3, and activated GSK3beta with a concomitant degradation of cyclin D1.	Gefitinib	13-22	cyclin D1	Homo sapiens	139-148